Approach to the immunosuppressed patient with pulmonary infiltrates.
D001228:Aspergillosis / Q000175:diagnosis; D001759:Blastomycosis / Q000175:diagnosis; D002177:Candidiasis / Q000175:diagnosis; D003453:Cryptococcosis / Q000175:diagnosis; D004917:Erythromycin / Q000008:administration & dosage; D005658:Fungi / Q000302:isolation & purification; D006660:Histoplasmosis / Q000175:diagnosis; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007877:Legionnaires' Disease / Q000175:diagnosis / Q000188:drug therapy; D008171:Lung Diseases / Q000209:etiology* / Q000276:immunology; D008172:Lung Diseases, Fungal / Q000175:diagnosis; D009164:Mycobacterium Infections / Q000276:immunology; D009617:Nocardia Infections / Q000175:diagnosis; D011014:Pneumonia / Q000382:microbiology / Q000473:pathology / Q000628:therapy; D011020:Pneumonia, Pneumocystis / Q000175:diagnosis; D011024:Pneumonia, Viral / Q000175:diagnosis
D004917:Erythromycin